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The aim of this study was to evaluate the expression of CC chemokine receptor 7 (CCR7) in squamous cell cancer of the tonsil
with respect to patterns of spread, relapse-free, overall and disease-specific survival. Eighty-four patients with squamous cell cancer
of the tonsil were identified. There was a male predominance of 3:1 and the median age at diagnosis was 53 (range 35–86) years.
The median duration of follow-up was 33 (range 2–124) months. There was a significant association between CCR7
immunopositivity and synchronous cervical nodal metastasis in patients with tonsillar cancer (Spearman’s correlation coefficient 0.564;
Po0.001). Relapse-free (P¼0.0175), overall (P¼0.0136) and disease-specific (P¼0.0062) survival rates were significantly lower in
patients whose tumours expressed high levels of CCR7. On multivariate analysis, high-level CCR7 staining predicted relapse-free
(hazard ratio 3.0, 95% confidence intervals 1.1–8.0, P¼0.026) and disease-specific (hazard ratio 10.2, 95% confidence intervals
2.1–48.6, P¼0.004) survival. Fifteen percent of patients with the highest level of tumour CCR7 immunopositivity relapsed with
systemic metastases. These data demonstrated that CCR7 expression was associated with cervical nodal and systemic metastases
from tonsillar cancers. High levels of CCR7 expression predicted a poor prognosis.
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The development of metastatic disease in loco-regional cervical
lymph nodes is a hallmark of squamous cell cancer of the head and
neck (SCCHN). Such is the predilection of this disease for
lymphatic metastasis that patients may present with pathologically
involved cervical nodes at any time during the natural history of
the disease (Munro et al, 2002). The phenomenon of cervical
nodal metastasis from an occult primary mucosal site in the
head and neck is well recognised (de Braud and al-Sarraf, 1993).
In addition, involved cervical nodes can present synchronously
with the primary tumour or metachronously as the first sign of
disease relapse.
The presence or absence of lymphatic metastasis is the most
important prognostic factor for patients with SCCHN (Layland
et al, 2005). On the basis of this fact, most patients who are
diagnosed as having SCCHN will have radiological investigations
such as computed tomography (CT) or magnetic resonance
imaging (MRI) in an attempt to identify nodal metastases. Even
if these tests suggest that the neck is not involved (clinically node-
negative or cN0 disease), patients frequently undergo prophylactic
treatment of the neck, either by elective neck dissection or
radiotherapy, in an attempt to ablate occult micrometastases. Such
additional treatment carries a significant morbidity for the patient.
Identification of a panel of biomarkers that would predict the
likelihood of nodal metastases would represent a useful tool for
patient selection for elective or adjuvant treatment of the neck.
Chemokines are small, secreted proteins with characteristic
cysteine motifs in their amino-acid sequences (Rossi and Zlotnik,
2000). Most members of the chemokine superfamily have four
cysteines and on this basis they have been classified into four
groups (CXC or a,C Co rb,Co rg and CXC3 or d) according to the
motif displayed by the first two cysteines. Chemokines interact
with their cognate receptors which are G-protein-coupled,
seven-transmembrane receptors (Gerard and Rollins, 2001).
Chemokines were initially shown to be involved in controlling
the targeted migration of haematopoietic cells, but more recently
they have been implicated in a diverse range of physiological and
pathological functions including wound healing, the control of
angiogenesis and the development of tumour metastases. Indeed,
there has been an evolving interest in the role of chemokines
and their receptors in the process of tumour metastasis in recent
years. A landmark study clearly demonstrated that breast cancer
cells that expressed the chemokine receptors, CXCR4 and CC
chemokine receptor 7 (CCR7), were capable of preferentially
homing to particular tissues (Muller et al, 2001).
CC chemokine receptor 7 is known to be the functional receptor
for secondary lymphoid organ chemokine. It acts by influencing
the migration of activated dendritic cells to regional lymph nodes.
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sSubsequent studies have demonstrated that CCR7 appears to play
an important role in the development of lymph node metastases
from oesophageal and gastric cancers (Mashino et al, 2002;
Ding et al, 2003; Yan et al, 2004). CC chemokine receptor 7 is also
expressed by human adult T-cell leukaemia cells that lodge in
lymph nodes (Hasegawa et al, 2000). Furthermore, expression of
CCR7 by murine melanoma cells has been shown to increase the
incidence of lymph node metastasis (Wiley et al, 2001).
Therefore, in this study we have evaluated the expression of
CCR7 in squamous cell cancer of the tonsil with particular
reference to the development of synchronous and/or metachro-
nous cervical nodal metastases and systemic relapse.
MATERIALS AND METHODS
Cell lines
Head and neck cancer cell lines were obtained from ATCC
(Manassas, VA, USA), from the Institute of Cancer Research/Royal
Marsden Hospital, London, UK (O-charoenrat et al, 2001) or
from the Ludwig Institute, London, UK. All cells were grown
in Dulbecco’s Modified Eagle’s medium (GIBCO-Invitrogen,
Carlsbad, CA, USA) supplemented with 10% heated-inactivated
fetal calf serum (Harlan Sera-Lab, Loughborough, UK).
Reverse transcription–PCR
PolyAþ mRNA was isolated using a QuickPrep micro mRNA
purification kit (GE Healthcare, Chalfont St Giles, UK) according
to the manufacturer’s instructions. mRNA was treated with DNase
I to avoid DNA contamination, extracted with phenol:chloroform
(5:1), and precipitated with ice-cold isopropanol and 3M Na
acetate (pH 5.2). The RNA was dissolved in RNase-free water, and
the Omniscript reverse transcription kit (Qiagen, Crawley, UK)
was used to convert mRNA into cDNA using random hexamer
pd(N)6 primers. cDNA was amplified by PCR using RedTaq DNA
polymerase (Sigma-Aldrich Co, Poole, UK) and specific CCR7
(Yanagihara et al, 1998) or CCL21 primers. Autoclaved double
deionised water was run to serve as a negative control. Twenty
microlitres of PCR product were electrophoresed in 1.2% agarose
gels containing ethidium bromide at 120V and the PCR products
were visualised using a UV transilluminator.
Western blotting
Cells in monolayer culture were washed twice with ice-cold
phosphate-buffered saline (PBS) and lysed on ice with lysis buffer
containing 150mM NaCl, 1mM EDTA, 50mM Tris, 1% Triton
X-100, 1mM NaF, 1mM NaVO3,1 0mgml
 1 TLCK, 5mM fenvalerate,
5mM bpVphen, 1mM PMSF, protease inhibitor cocktail (1:100),
phosphatase inhibitor cocktail I (1:100) and phosphatase inhibitor
cocktail II (1:100) (all from Sigma). After incubation on ice for
15min, lysates were centrifuged at 12000r.p.m. for 10min and
the supernatant was harvested. Protein electrophoresis was
performed using the NUPAGE Novex Bis-Tris Pre-Cast Gel
system according to the manufacturer’s instructions (Invitrogen).
Electrophoresed proteins were transferred onto PVDF membranes
using the NUPAGE transfer system with the XCell II blot module
(Invitrogen) according to the manufacturer’s instructions.
Membranes were blocked with 5% milk in TNT solution (50mM
Tris-HCl pH8.0, 150mM NaCl, 0.1% Tween 20) overnight
at 41C. After incubation with rabbit anti-CCR7 (Epitomics Inc.,
Burlingame, CA, USA) and mouse anti-b-actin (Abcam Ltd,
Cambridge, UK) primary monoclonal antibodies, membranes were
washed in TNT and probed with HRP-conjugated secondary
antibody at room temperature for 1–2h. The protein of interest
was detected using ECL or ECL plus chemiluminescent Western
blotting detection reagent and Hyperfilm ECL (Amersham plc.,
Little Chalfont, UK).
Patients
Patients who had been diagnosed with squamous cell cancer of the
tonsil during the years 1990–2003 were identified from the head
and neck cancer databases of the Royal Marsden and St George’s
Hospitals. Data on the primary tumour stage and the presence of
cervical nodal metastases at the time of diagnosis were obtained
from the databases. In addition, data were obtained on subsequent
development of cervical nodal or systemic tumour metastases.
Archival paraffin-embedded tumour tissue was obtained in each
of these cases. Specimens from a total of 84 patients who had
been diagnosed with squamous cell cancer of the tonsil in
whom adequate follow up data were available were processed
and analysed. There was a male predominance of 3:1 (63 males
and 21 females). The median age at diagnosis was 53 (range
35–86) years. The median duration of follow-up was 33 (range
2–124) months.
Staging
A summary of tumour and nodal stage at presentation as defined
by the International Union Against Cancer TNM classification
(1997) is presented in Table 1. As can be seen from these data,
the majority of patients presented with node-positive late-stage
disease. The distribution of patients according to the American
Joint Committee on Cancer staging system was as follows: Stage I
(T1N0M0)—3 patients (3.6%); Stage II (T2N0M0)—11 patients
(13.1%); Stage III (T3N0M0, T1-3N1M0)—22 patients (26.1%);
Stage IVA (T4N0-1M0, T1-4N2M0)—41 patients (48.8%); and
Stage IVB (T1-4N3M0)—7 patients (8.3%).
Treatment
Over the 13-year period spanned by the study, there was some
variability in the standard departmental treatment protocols.
However, most patients underwent excision of the primary
tumour (n¼63), with or without neck dissection (n¼39) and
post-operative radiotherapy to the tonsil and neck (n¼59). In two
patients, post-operative concomitant chemoradiotherapy (cisplatin
100mgm
 2 on days 1 and 29) was administered. Seventeen
patients received primary radical radiotherapy and five patients
underwent induction chemotherapy (cisplatin 100mgm
 2 on day
1, 5-fluorouracil 1000mgm
 2 on days 1–4 for two cycles) followed
by radical chemoradiotherapy.
Follow-up
The rates of local control, loco-regional control and survival were
calculated using the Kaplan–Meier method. The cause of death
Table 1 Summary of TNM stage at presentation in the 84 patients with
squamous cell carcinoma of the tonsil
N0 N1 N2a N2b N2c N3 Total
T1 3 7 6 3 0 1 20
T2 11 9 4 10 1 2 37
T3 5 1 3 7 1 2 19
T4 3 1 1 0 1 2 8
Total 22 18 14 20 3 7 84
N0¼no nodal metastasis; N1¼single ipsilateral cervical nodal metastasis o3cmin
diameter; N2a¼single ipsilateral cervical nodal metastasis 43cm but o6cm
in diameter; N2b¼more than one ipsilateral cervical nodal metastases, none
46cm in diameter; N2c¼bilateral or contralateral cervical nodal metastasis,
none 46cm in diameter; N3¼cervical nodal metastasis 46cm in diameter.
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swas used to estimate disease-specific survival. Overall survival was
calculated from the date of diagnosis to the date of last follow-up
or death from any cause, and disease-specific survival from the
date of diagnosis to the date of last follow-up or death from
tonsillar cancer. Relapse-free survival was calculated from the date
of treatment to the date of documentation of clinical recurrence or
death. The impact of salvage treatment following local, regional or
systemic failure is not considered in these results, other than for its
contribution to the disease-specific survival. The censor date for
analysis was December 2005.
Immunohistochemistry
Formalin-fixed, paraffin-embedded 3-mm sections were cut and
placed on 0.1% poly-L-lysine slides (Sigma), dried for 1h and
stored at room temperature until use. Normal archival human
spleen and tonsil tissue specimens were identified as positive and
negative controls, respectively. In addition, in many of the tumour
specimens, the presence of adjacent normal tonsillar mucosa
served as a useful internal negative control. Antigen retrieval was
not necessary. Immunohistochemical staining was performed
using a standard avidin-biotin peroxidase method. Slides were
dewaxed and rehydrated through solutions of xylene, alcohol and
water according to standard protocols. Endogenous peroxide was
blocked with 0.3% hydrogen peroxide solution for 30min and the
slides were then incubated with anti-CCR7 antibody (Abcam Ltd)
for 2h at room temperature. Anti-CCR7 is a goat polyclonal
antibody that was raised against mouse CCR7 by immunising with
the synthetic 21-mer DPGKPRKNVLVVALLVIFQVC. It also
recognises the human CCR7 protein. Following incubation with
anti-CCR7, the slides were rinsed three times in PBS solution and
incubated for 2h at room temperature with biotinylated anti-
mouse IgG. Slides were again rinsed three times in PBS solution,
and subsequently colorimetric visualisation was achieved by
addition of 50ml 3,30-diaminobenzidine (BDH Laboratory
Supplies, Poole, UK) solution at a concentration of 0.3mgml
 1.
Sections were counterstained with Mayer’s hematoxylin.
Scoring of staining
All slides were reviewed by the two pathologists, both with
specialist expertise in head and neck cancer, and by Pitkin. The
observers were blinded to the identity of the patients and to any
details regarding clinical stage, patterns of failure or treatment
outcome. The pathologists assessed the adequacy of immunostain-
ing in test slides and in negative and positive control slides, and
then selected representative areas of tumour for counting. All three
observers counted a minimum of 200 tumour cells and agreed a
score for each case (see below). Positive immunostaining for CCR7
was seen predominantly in the cell membrane and also in the cell
nucleus; there was some variation in the degree of immuno-
staining. Tumour cells, where there was only patchy weak staining,
were counted as negative; cells with uniformly clear staining,
regardless of its intensity, were counted as positive. The following
scoring system was devised based on the proportion of tumour
cells expressing CCR7. Tumours with o1% of tumour cells
expressing CCR7 were scored as ‘ ’; tumours with 1–33% of
tumour cells expressing CCR7 were scored as ‘þ’; tumours with
34–66% of tumour cells expressing CCR7 were scored as ‘þþ’;
and tumours with 67% or more of tumour cells expressing CCR7
were scored as ‘þþþ’.
Statistical analysis
The primary aim was to investigate the association between the
level of CCR7 staining in the primary tumour and the nodal stage
at diagnosis. To assess the strength of this relationship, if any,
Spearman’s rank correlation coefficient was calculated. Secondary
end points included cervical nodal and systemic disease recur-
rence, relapse-free, disease-specific and overall survival. These
were assessed using the Kaplan–Meier method, and differences
between the patients with low and high levels of CCR7 staining
were compared using the log-rank test. The effect of age, tumour
stage and CCR7 staining intensity on the various survival
parameters was assessed using Cox regression analysis. Data were
updated to December 2005.
RESULTS
CCR7 expression is detected by RT–PCR and Western
blotting in head and neck cancer cell lines
CC chemokine receptor 7 was found to be expressed in all cell lines
tested with highest levels in 005A, 005B, HN3, HN4 and HN6
(Figure 1). However, the expression of its ligand CCL21 was
detectable in only one cell line (013) determined at 40–45 cycles of
RT–PCR. The expression of CCL19, another ligand for CCR7, was
very low or undetectable in all cell lines tested (data not shown).
CC chemokine receptor 7 was also detectable by Western blotting
in all cell lines tested. Lower levels were seen in 013 and CAL27
cells and these findings were reasonably consistent with the RNA
expression by RT–PCR.
CCR7 immunostaining correlates with cervical nodal
metastasis
Representative examples of tumours in each of these groups are
shown in Figure 2A–D. Staining of normal human spleen (positive
control) and tonsil (negative control) is shown in Figure 2E and F,
respectively. The CCR7 immunopositivity score in the primary
tumour is summarised according to the nodal stage at presentation
in Table 2. This demonstrates a strong association between
CCR7 expression and synchronous nodal metastasis in patients
with tonsillar cancer. Therefore, only 1 out of 11 (9.1%) patients
with negative CCR7 immunohistochemistry had nodal involve-
ment at presentation, in contrast to 8 out of 13 (61.5%) patients
with ‘þ’ staining, 24 out of 27 (88.9%) patients with ‘þþ’
staining and 29 out of 33 (87.8%) patients with ‘þþþ’ staining
(Figure 3A). Similarly, the degree of CCR7 immunopositivity was
directly correlated with the extent of nodal metastasis at diagnosis
(Figure 3B) (Spearman’s correlation coefficient 0.564; Po0.001).





















































































Figure 1 Expression of CCR7 in 10 head and neck cancer cell lines.
(A). RT–PCR for expression of CCR7 (and one of its ligands CCL21).
(B) Western blot analysis. In both cases, b-actin has been used as a loading
control.
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sCCR7 immunostaining correlates with relapse-free survival
Analysis of CCR7 immunostaining in the primary tumour with
respect to subsequent disease relapse demonstrated a nonsignifi-
cant trend (P¼0.096; Figure 4A). When the groups were divided
into those with low (‘ ’o r‘þ’) or high (‘þþ’o r‘þþþ’) levels
of CCR7 staining, a statistically significant difference was apparent
(P¼0.0175; Figure 4B). The patterns of relapse are presented in
Figure 4C. It is interesting to note that the rates of cervical nodal
relapse in the different immunostaining groups were essentially
the same at approximately 20%. However, patients with ‘þþ’o r
‘þþþ’ staining in the primary tumour were more likely to
develop local recurrence or systemic metastases. Indeed, 15% of
patients with primary tumours that displayed the highest levels of
immunostaining for CCR7 developed systemic metastatic disease.
In fact, three patients who presented with cN0 neck disease
developed systemic metastases as their first sign of recurrent
disease. In two cases, the primary tumour stained ‘þþþ’ and in
the other it stained ‘þþ’ for CCR7.
CCR7 immunostaining predicts overall and disease-
specific survival
Patients with primary tumours that displayed high-level (‘þþ’o r
‘þþþ’) immunostaining for CCR7 had significantly worse overall
and disease-specific survival rates than patients with low level (‘ ’
or ‘þ’) immunostaining (Figures 5 and 6, respectively). Median
overall survival was 7.2 (95% confidence intervals 2.8–11.5) years
for the group with high-level immunostaining for CCR7, but was
not reached in the group with low-level immunostaining. At 6 years,
only 52% of the high-level immunostaining group was alive,
compared with 76% of the low-level immunostaining group. If the
data were analysed according to disease-specific survival, there was
a very significant difference between patients with low- and high-
level immunostaining for CCR7 (P¼0.0062). For patients with high-
level immunostaining, the median disease-specific survival was
7.2 (95% confidence intervals 5.8–8.6) years. In contrast, median
disease-specific survival was not reached for the patients with low-
level immunostaining for CCR7. The 2-year disease-specific survival
rates for the patients with low- and high-level immunostaining for
CCR7 were 96 and 83%, respectively. The corresponding survival
rates at 4 and 6 years were 91 and 65% and 91 and 61%, respectively.
Five patients (6%) died of second primary tumours (four lung,
one stomach and one oesophageal cancer), three patients (3.6%)
died as a result of post-operative complications and three (3.6%)
patients died of intercurrent illnesses.
Univariate and multivariate analysis confirms CCR7
staining as a significant predictor of relapse-free and
disease-specific survival
Cox regression analysis was performed on the data for both




Figure 2 Representative examples of immunostaining for CCR7. (A)‘  ’ CCR7 immunostaining in primary SCC tonsil. (B)‘þ’ CCR7 immunostaining in
primary SCC tonsil. (C)‘ þþ’ CCR7 immunostaining in primary SCC tonsil. (D)‘ þþþ’ CCR7 immunostaining in primary SCC tonsil. (E) Positive
control CCR7 staining in human spleen. (F) Negative control CCR7 staining in normal human tonsil tissue.
Table 2 CCR7 immunostaining scores in the primary tumours according
to nodal stage at initial disease presentation
Score   Score + Score ++ Score +++ Total
N0 10 (45.4) 5 (22.7) 3 (13.6) 4 (18.3) 22
N1 0 (0) 8 (44.4) 6 (33.3) 4 (22.2) 18
N2a 0 (0) 0 (0) 7 (50) 7 (50) 14
N2b 1 (5) 0 (0) 8 (40) 11 (55) 20
N2c 0 (0) 0 (0) 1 (33.3) 2 (66.7) 3
N3 0 (0) 0 (0) 2 (28.5) 5 (71.5) 7
Total 11 13 27 33 84
CCR7¼CC chemokine receptor 7; N0¼no nodal metastasis; N1¼single ipsilateral
cervical nodal metastasis o3cm in diameter; N2a¼single ipsilateral cervical nodal
metastasis 43cm but o6cm in diameter; N2b¼more than one ipsilateral cervical
nodal metastases, none 46cm in diameter; N2c¼bilateral or contralateral cervical
nodal metastasis, none 46cm in diameter; N3¼cervical nodal metastasis 46cmin
diameter. Figures in parentheses represent percentages.
CCR7 Expression in tonsil cancer
L Pitkin et al
673




















sonly T stage (P¼0.016) and high-level (‘þþ’o r‘þþþ’) CCR7
immunostaining (P¼0.022) were statistically significant on
univariate analysis. Each of these factors remained significant in
multivariate analysis. For disease-specific survival, T stage
(P¼0.001), N stage (P¼0.005) and high-level CCR7 immuno-
staining (P¼0.015) were statistically significant on univariate
analysis. All of these factors also remained significant in multi-
variate analysis (Tables 3–6).
DISCUSSION
The development of cervical nodal metastases is a highly
significant adverse prognostic feature in patients with SCCHN.
However, the molecular basis of tumour cell migration and lymph
node metastasis from primary SCCHN is still not fully under-
stood. Recent studies have suggested that normal chemokine
signalling pathways that play a central role in lymphoid cell
migration and homeostasis can be subverted in SCCHN (and
other tumours) to mediate specific patterns of tumour spread. CC
chemokine receptor 7 is known to influence the migration of
activated dendritic cells to regional lymph nodes and appears
to play a similar role in gastric, oesophageal and head and
neck cancers (Mashino et al, 2002; Ding et al, 2003; Wang et al,
2004; Yan et al, 2004). Mashino et al (2002) showed that 66%
of gastric carcinoma samples from 64 patients expressed CCR7
and those patients with CCR7-positive tumours had a signi-
ficantly worse prognosis. Ding et al (2003) corroborated these
findings with the demonstration that CCR7 mediated lymph
node metastasis in oesophageal cancers. Wang et al (2004)
reported upregulation of CCR7 expression in metastatic
tumour lines from 14 patients with SSCHN. Furthermore,
Wang et al (2005) have shown that CCR7-triggered signalling
through the phosphoinositide-3-kinase (PI-3K/protein kinase B
(PKB/AKT) signalling cascade is directly involved in chemo-
taxis and tumour cell invasion of matrigel in vitro in two SCCHN
cell lines.
In this study, we found a striking correlation between CCR7
immunostaining in primary tonsillar cancers and the presence of
cervical nodal metastases at initial diagnosis and subsequent
relapse-free, overall and disease-specific survival rates. At pre-
sentation, only one patient with a CCR7-negative primary tumour
had nodal disease but every patient with ‘þþþ’ staining had
advanced neck disease (N2 or N3). Of course, given the various
treatment protocols that were used during the study period and the
fact that only 39 of the patients had a pathologically staged neck,
there is some uncertainty about the security of the initial diagnosis
of cervical nodal disease, although this factor has no effect
on the observed relapse-free, overall and disease-specific survival
rates. The only patients who underwent neck dissection had
clinically or radiologically positive neck disease. The fact that none
of the 39 patients who underwent a neck dissection had a
pathologically negative neck attests to the accuracy of diagnosis of
clinically overt neck disease before surgery. By comparison,
no patient with a clinically and radiologically negative neck
underwent an elective neck dissection. Therefore, the data on neck
stage for these patients were derived exclusively from clinical
examination and CT/MRI scans. Therefore, the greatest
uncertainty exists for these 22 patients with clinically node-
negative necks who did not undergo neck dissection. There is no
way of knowing what the pathological neck stage would have
been in these patients. However, it is possible to speculate that
some of these clinically node-negative patients may have
been those who developed nodal or systemic relapse during
follow-up. The other 23 out of 45 patients who were staged
clinically were recorded as having cervical nodal disease and, given
the results of the patients who underwent surgical staging of the
neck, it is reasonable to accept that these patients truly had cervical
nodal involvement.
The correlation between CCR7 immunostaining in primary
tonsillar cancers and the presence of cervical nodal metastases at
initial diagnosis may be of interest in selecting patients for elective
treatment of the cervical nodes in the setting of a clinically negative
neck. Analysis of the data from this study show that by considering
‘ ’ staining for CCR7 to mean no nodal metastasis and ‘þ’, ‘þþ’
or ‘þþþ’ CCR7 staining to mean the presence of nodal
metastasis, the test would have a negative predictive value of
90% and a positive predictive value of 80%. Most head and
neck oncologists use a threshold risk of cervical nodal metastasis
of 20% for recommending elective nodal treatment. Such elective
therapy may take the form of surgical dissection or cervical nodal
irradiation which, by definition, is unnecessary in most (upto 80%)
patients. Both elective neck dissection and elective irradiation
expose the patient to potentially serious adverse effects, including
accessory or hypoglossal nerve damage, shoulder dysfunction and
radiation-induced second malignancy. Therefore, a reliable pre-
dictor (or a panel of predictors) of the risk of nodal metastasis
would serve as an extremely useful clinical tool for more accurate
selection of patients for elective treatment of cervical lymph nodes.
CC chemokine receptor 7 immunostaining appears to represent
one such potentially useful marker.
CC chemokine receptor 7 immunostaining in the primary































































Figure 3 (A) CCR7 immunostaining scores correlate with cervical nodal
metastasis. (B) Rates of cervical nodal metastasis according to CCR7
immunostaining score. Spearman’s correlation coefficient is 0.564;
Po0.001.
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spresentation, but also the risk of subsequent relapse. Twelve
patients with high-level CCR7 expression in the primary tumour
presented with N0 or N1 disease but went on to develop disease
relapse. Analysis of the patterns of recurrence sheds further light
on the biological importance of CCR7 expression. Systemic
metastatic disease was the first sign of relapse in seven patients
(8.3%) and in all cases there was positive immunostaining for
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Figure 4 (A). Relapse-free survival rates for patients in the four categories ( , þ, þþ and þþþ) of CCR7 immunostaining (P¼0.096). (B)
Relapse-free survival rates were significantly different for patients with low (  or þ) and high (þþ or þþþ) levels of CCR7 immunostaining
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Figure 5 Overall survival rates were significantly different for patients
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Figure 6 Disease-specific survival rates were significantly different for
patients with low (  or þ) and high (þþor þþþ) levels of CCR7
immunostaining (P¼0.0062).
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sCCR7 at presentation. Remarkably, in three of these patients there
was no evidence of nodal metastasis either at presentation or in
relapse. It can, therefore, be postulated that high-level immuno-
staining for CCR7 may serve as a predictive marker of systemic
metastatic disease. This series of patients received treatment
at a time when combined chemoradiotherapy was not widely
used in our practice. Therefore, the incidence of systemic
metastasis is unlikely to have been influenced by the effect of
chemotherapy on subclinical micrometastasis. Despite the fact that
adjuvant chemotherapy has not been shown to improve the
outcome in head and neck cancer (Pignon et al, 2000), the data
from this study raise the prospect of selecting high-risk patients
for adjuvant trials of new-targeted agents.
CC chemokine receptor 7 immunostaining was also correlated
strongly with overall and disease-specific survival. These findings
cannot be explained solely in terms of the fact that patients with
high-level staining for CCR7 were more likely to have nodal disease
at diagnosis (a factor that is known to be strongly predictive of
outcome), because CCR7 immunostaining was an independent
predictor of disease-specific survival on multivariate analysis. This
observation may have been due, at least in part, to the effects of
CCR7 on resistance to adjuvant radiation therapy. Since CCR7
signalling in normal immune cells mediates a pro-survival
signal through the PKB/AKT cascade (Pilkington et al, 2004;
Sanchez-Sanchez et al, 2004), it is also possible that this
pathway may influence outcome in response to treatment in head
and neck cancers. Therefore, patients with primary tumours that
express high levels of CCR7 may be good candidates for enrolment
in studies of new agents that target the CCR7-PI-3K-PKB/AKT
axis. It is of note that the improvement in disease-specific survival
also translated into a significant increase in overall survival.
Therefore, CCR7 immunostaining in the primary tumour may
provide an important prognostic marker of overall survival and
may be a useful guide to selection of patients for treatment
intensification.
In summary, in this study we have shown a strong correlation
between CCR7 immunostaining in the primary tumour and the
presence of synchronous cervical nodal metastasis. Furthermore,
a statistically significant association between CCR7 staining
and relapse-free and disease-specific survival was demon-
strated. Interestingly, it appears that, in addition to predicting
nodal disease, CCR7 may also serve as a predictor of systemic
metastasis.
ACKNOWLEDGEMENTS
This work was funded by charitable donations in memory of Mr
Peter Harrington.
Table 3 Univariate analysis of relapse-free survival
Factor N Hazard ratio (95% CI) P-value
Age
Per year 84 1.02 (0.99–1.05) 0.311
Nodes
No 24 1 0.546
Yes 60 1.27 (0.58–2.77)
T stage
T1 20 1
T2 37 1.25 (0.48–3.26) 0.016
T3 19 1.23 (0.40–3.83)
T4 8 4.72 (1.47–15.09)
N stage
N0 24 1
N1 16 1.20 (0.42–3.43) 0.248
N2 37 1.08 (0.45–2.57)
N3 7 2.80 (0.91–8.59)
CCR7
Low ( , +) 24 1 0.022
High (++, +++) 60 3.10 (1.18–8.13)
Table 4 Multivariate analysis of relapse-free survival
Factor N Hazard ratio (95% CI) P-value
T stage
T1 20 1
T2 37 1.37 (0.52–3.60) 0.521
T3 19 1.13 (0.36–3.51) 0.838
T4 8 4.37 (1.37–13.94) 0.013
CCR7
Low ( ,+ ) 2 4 1
High (++, +++) 60 3.02 (1.14–8.02) 0.026
Table 5 Univariate analysis of disease-specific survival
Factor N Hazard ratio (95% CI) P-value
Age
Per year 84 0.99 (0.95–1.04) 0.751
Nodes
No 24 1 0.762
Yes 60 1.15 (0.46–2.87)
T stage
T1 20 1
T2 37 1.18 (0.36–3.84) 0.001
T3 19 0.92 (0.21–4.11)
T4 8 6.14 (1.68–22.39)
N stage
N0 24 1
N1 16 1.37 (0.42–4.51) 0.005
N2 37 0.64 (0.20–2.04)
N3 7 4.69 (1.38–15.88)
CCR7
Low ( , +) 24 1 0.015
High (++, +++) 60 6.2 (1.4–26.7)
Table 6 Multivariate analysis of disease-specific survival
Factor N Hazard ratio (95% CI) P-value
T stage
T1 20 1
T2 37 0.98 (0.27– 3.51) 0.973
T3 19 0.67 (0.15–3.14) 0.615
T4 8 3.77 (0.99–14.28) 0.051
N stage
N0 24 1
N1 16 0.65 (0.17–2.45) 0.521
N2 37 0.22 (0.06–0.80) 0.022
N3 7 1.17 (0.27–5.05) 0.832
CCR7
Low ( , +) 24 1 0.004
High (++, +++) 60 10.2 (2.1–48.6)
CCR7 Expression in tonsil cancer
L Pitkin et al
676





















De Braud F, al-Sarraf M (1993) Diagnosis and management of squamous
cell carcinoma of unknown primary tumor site of the neck. Semin Oncol
20: 273–278
Ding Y, Shimada Y, Maeda M, Kawabe A, Kaganoi J, Komoto I, Hashimoto
Y, Miyake M, Hashida H, Imamura M (2003) Association of CC
chemokine receptor 7 with lymph node metastasis of esophageal
squamous cell carcinoma. Clin Cancer Res 9: 3406–3412
Gerard C, Rollins BJ (2001) Chemokines and disease. Nat Immunol 2:
108–115
Hasegawa H, Nomura T, Kohno M, Tateishi N, Suzuki Y, Maeda N,
Fujisawa R, Yoshie O, Fujita S (2000) Increased chemokine receptor
CCR7/EBI1 expression enhances the infiltration of lymphoid organs by
adult T-cell leukaemia cells. Blood 95: 30–38
Layland MK, Sessions DG, Lenox J (2005) The influence of lymph node
metastasis in the treatment of squamous cell carcinoma of the oral cavity,
oropharynx, larynx and hypopharynx: N0 versus N+. Laryngoscope 115:
629–639
Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, Inoue H,
Mori M (2002) Expression of chemokine receptor CCR7 is associated with
lymph node metastasis of gastric carcinoma. Cancer Res 62: 2937–2941
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T,
Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E,
Zlotnik A (2001) Involvement of chemokine receptors in breast cancer
metastasis. Nature 410: 50–56
Munro AJ, MacDougall RH, Stafford ND (2002) In: Price P, Sikora K (eds).
Head and Neck Chapter in Treatment of Cancer. pp 313–390. London,
UK: Chapman and Hall Medical
O-charoenrat P, Rhys-Evans P, Eccles S (2001) Characterization of ten
newly-derived human head and neck squamous carcinoma cell lines with
special reference to c-erbB proto-oncogene expression. Anticancer Res
21: 1953–1963
Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added
to locoregional treatment for head and neck squamous-cell carcinoma:
three meta-analyses of updated individual data. MACH-NC Collaborative
Group. Meta analysis of chemotherapy on head and neck cancer. Lancet
355: 949–955
Pilkington KR, Clark-Lewis I, McColl SR (2004) Inhibition of genera-
tion of cytotoxic T lymphocyte activity by a CCL19/macro-
phage inflammatory protein (MIP)-3beta antagonist. J Biol Chem 279:
40276–40282
Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors.
Ann Rev Immunol 18: 217–242
Sanchez-Sanchez N, Riol-Blanco L, de la Rosa G, Puig-Kroger A, Garcia-
Bordas J, Martin D, Longo N, Cuadrado A, Cabanas C, Corbi AL,
Sanchez-Mateos P, Rodriguez-Fernandez JL (2004) Chemokine receptor
CCR7 induces intracellular signaling that inhibits apoptosis of mature
dendritic cells. Blood 104: 619–625
Wang J, Xi L, Hunt JL, Gooding W, Whiteside TL, Chen Z, Godfrey TE,
Ferris RL (2004) Expression pattern of chemokine receptor 6 (CCR6) and
CCR7 in squamous cell carcinoma of the head and neck identifies a novel
metastatic phenotype. Cancer Res 64: 1861–1866
Wang J, Zhang X, Thomas SM, Grandis J, Wells A, Chen ZG, Ferris RL
(2005) Chemokine receptor 7 activates phosphoinositide-3 kinase-
mediated invasive and prosurvival pathways in head and neck cancer
cells independent of EGFR. Oncogene 24: 5897–5904
Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST (2001) Expression of
CC chemokine receptor-7 and regional lymph node metastasis of B16
murine melanoma. J Natl Cancer Inst 93: 1638–1643
Yan C, Zhu ZG, Yu YY, Ji J, Zhang Y, Ji YB, Yan M, Chen J, Liu BY,
Yin HR, Lin YZ (2004) Expression of vascular endothelial growth
factor C and chemokine receptor CCR7 in gastric carcinoma and their
values in predicting lymph node metastasis. World J Gastroenterol 10:
783–790
Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y (1998) EB1/
CCR7 is a new member of dendritic cell chemokine receptor that is
upregulated upon maturation. J Immunol 161: 3096–3102
CCR7 Expression in tonsil cancer
L Pitkin et al
677
British Journal of Cancer (2007) 97(5), 670–677 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s